Global Advancements in Bladder Cancer Webcast (2023)

Global Advancements in Bladder Cancer (2023) is an exciting new global educational initiative featuring a series of three interactive, case-based, live virtual courses conducted in English, Spanish and Portuguese.  For each session, a Moderator will engage three other subject matter experts in an interactive, interview-style presentation and discussion.

Based on the findings from the 2022 AUA global survey and needs assessment in bladder cancer, the AUA has developed this new series of virtual courses to update urologists on the latest advancements in bladder cancer care. This course will address new and emerging treatment options for non‐muscle invasive (NMIBC) and muscle‐invasive bladder cancer (MIBC) with a focus on identifying side effects and interventions, review of guidelines specific to first and second line therapies, timing and usage of neoadjuvant and adjuvant systemic therapy, BCG shortage and the urologists role in clinical trial enrollment. Currently available agents as well as those in development will be discussed.

Each activity will be recorded and feature subject matter experts from around the world.  The webcasts will be made available on AUAUniversity and AUA’s YouTube channel for on‐demand viewing for up to one year. Additionally, the audio of the virtual course presented in English will be released as an episode on AUA’s very popular podcast.

Learners will also be provided with links to access additional resources including the AUA’s clinical guidelines discussed during the virtual courses and associated patient resources.

ACKNOWLEDGEMENTS

This educational series is supported by an independent educational grant from AstraZeneca.

Target Audience

  • Urologists
  • Residents

Learning Objectives

After participating in this educational series, participants will be able to:

  1. Delineate key factors to risk stratify patients with NMIBC and invasive bladder cancer.
  2. Review guidelines focused on first‐ and second‐line therapies for NMIBC and invasive bladder cancer.
  3. Describe emerging treatment options with intravesical and systemic therapies for patients in an era of BCG shortage and for patients with BCG unresponsive disease and determine the appropriate timing and use of neoadjuvant and adjuvant systemic therapy for invasive bladder cancer.
  4. Identify side effects and possible interventions to ameliorate side effects for these therapies.
  5. Recognize the urologist’s role in clinical trials and how to overcome obstacles to clinical trial enrollment. 
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
06/21/2023
Course expires: 
06/21/2024
Part of: 
Global Advancements in Bladder Cancer (2023)
Rating: 
0

FACULTY DISCLOSURES

For a full list of faculty disclosures, please visit the faculty tab on the Global Advancements in Bladder Cancer - English Live Course activity. 

EDUCATION COUNCIL DISCLOSURES

PDF iconEducation Council Disclosures

COI REVIEW WORK GROUP DISCLOSURES

PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

 

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by view the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 1.50 hour

Release Date: June, 2023
Expiration Date: June, 2024

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

 

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.